Halozyme Therapeutics Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $316.6M | $146.7M | $135.1M | $75.3M | $54.8M | $42.3M | $56.1M | $13.6M |
| Cost of Revenue | $31.2M | $33.2M | $29.2M | $22.7M | $6.2M | $1.1M | $257.8K | $985.3K |
| Gross Profit | $285.5M | $113.5M | $105.8M | $52.6M | $48.6M | $41.2M | $55.8M | $12.6M |
| Gross Margin | 90.2% | 77.4% | 78.3% | 69.8% | 88.6% | 97.4% | 99.5% | 92.8% |
| Operating Expenses | ||||||||
| Research & Development | $150.6M | $150.8M | $93.2M | $79.7M | $96.6M | $70.0M | $57.6M | $51.8M |
| SG&A Expense | $53.8M | $45.9M | $40.0M | $35.9M | $32.3M | $24.8M | $18.1M | $15.1M |
| Operating Income | $81.0M | $-83.2M | $-27.5M | $-63.0M | $-80.4M | $-53.6M | $-19.8M | $-54.3M |
| Operating Margin | 25.6% | -56.7% | -20.3% | -83.7% | -146.8% | -126.7% | -35.4% | -398.2% |
| Interest Expense | $22.0M | $20.0M | $5.2M | $5.6M | $3.3M | $0 | $0 | — |
| Pretax Income | $61.6M | $-101.9M | $-32.2M | $-68.4M | — | — | — | — |
| Income Tax Expense | $-1.4M | $1.2M | $0 | $0 | — | — | — | — |
| Net Income | $63.0M | $-103.0M | $-32.2M | $-68.4M | $-83.5M | $-53.6M | $-19.8M | $-53.2M |
| Net Margin | 19.9% | -70.2% | -23.9% | -90.8% | -152.3% | -126.5% | -35.2% | -390.8% |
| EPS (Basic) | $0.46 | $-0.81 | $-0.25 | $-0.56 | $-0.74 | $-0.48 | $-0.19 | $-0.56 |
| EPS (Diluted) | $0.45 | $-0.81 | $-0.25 | $-0.56 | $-0.74 | $-0.48 | $-0.19 | $-0.56 |
| Shares Outstanding (Basic) | 136.4M | 128.0M | 126.7M | 125.7M | 114.5M | 112.7M | 104.0M | 100.6M |
| Shares Outstanding (Diluted) | 139.1M | 128.0M | 126.7M | 125.7M | 114.5M | 112.7M | 104.0M | 100.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |